Inactivity of imatinib in gastrointestinal stromal tumors (GISTs) harboring a KIT activation-loop domain mutation (exon 17 mutation pN822K)

par Spitaleri G, Biffi R, Barberis M, Fumagalli C, Toffalorio F, Catania C, Noberasco C, Lazzari C, de Marinis F, De Pas T
Publié 2015-08-01

Endocrinological and clinical evaluation of two doses of formestane in advanced breast cancer.

par Bajetta, E., Zilembo, N., Buzzoni, R., Noberasco, C., Di Leo, A., Bartoli, C., Merson, M., Sacchini, V., Moglia, D., Celio, L.
Publié 1994

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.

par Zilembo, N., Noberasco, C., Bajetta, E., Martinetti, A., Mariani, L., Orefice, S., Buzzoni, R., Di Bartolomeo, M., Di Leo, A., Laffranchi, A.
Publié 1995

Antitumor activity of sorafenib and imatinib in a patient with thymic carcinoma harboring c-KIT exon 13 missense mutation K642E

par Catania C, Conforti F, Spitaleri G, Barberis M, Preda L, Noberasco C, Lazzari C, Toffalorio F, de Marinis F, Manzotti M, De Pas TM
Publié 2014-05-01